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INTRODUCTION
espite years of clinical study, there are still many unan-
swered questions regarding postmastectomy radiation
(PMRT). It is accepted that PMRT is not required for most women
with noninvasive disease or stage I disease. Randomized clinical
trials studying radiation treatments for women with stage II or III
breast cancers have shown that the addition of radiation after
mastectomy can reduce locoregional recurrence (LR) rates,
which then improves survival.  However, other data have indicat-
ed that the risk of LR after mastectomy and chemotherapy is low
for patients with small tumors and one to three positive lymph
nodes (LN), leading some to question whether PMRT is useful for
this group (1).
The overall importance of local tumor control in the management
of breast cancer, specifically the influence of local control on sur-
vival, remains one of the fundamental questions for oncologists
(2). PMRT is often recommended for patients at high risk for LR
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BACKGROUND: Postmastectomy radiotherapy has been the topic for many debates
over several years about its role on locoregional control as well as overall survival in
premenopausal and postmenopausal breast cancer patients. 
METHODS: From 1994 till 1999, 233 patients underwent modified radical mastectomy
for breast cancer. Among them there was 92 premenopausal patients (median age was
44 years) and 141 postmenopausal patients (median age was 60 years). Traditional
prognostic factors were used to assess risk of locoregional recurrence: 84 patients
were node-negative, 71 patients had 1 to 3 lymph nodes positive, and 71 patients had
4 and more positive lymph nodes; 103 patients had tumor less than 3 cm diameter and
130 patients had tumors grater than 3 cm. According to this, postmastectomy radio-
therapy was applied in 125 patients of whom 117 patients (94%) had also adjuvant sys-
temic therapy (chemotherapy and/or hormonal therapy).
RESULTS: The locoregional recurrence was observed in 42 patients while 191 patients
were free of (median follow-up time was 49 months). Locoregional recurrence devel-
oped in 10 patients who had postmastectomy radiotherapy and in 32 patients who did
not had postmastectomy radiotherapy (p=0.0001). In the group of patients with
locoregional recurrence event 5-year overall survival was 28% while 70% in the group
of patients free of (p=0.00001). There was statistically significant advantage for post-
mastectomy radiotherapy in the group of patients with 1 to 3 positive lymph nodes as
well as for 4 and more positive lymph nodes group (p=0.0008). In addition there was
statistically significant difference among postmastectomy radiotherapy group and no
postmastectomy radiotherapy group for disease free survival (74% vs. 50%, 5-year dis-
ease free survival, p=0.0001) and overall survival (71% vs. 53%, 5-year overall sur-
vival, p=0.0422).
CONCLUSION: Postmastectomy radiotherapy reduces locoregional recurrence rate
and improves overall survival in premenopausal and postmenopausal breast cancer
patients with tumors grater than 3cm diameter and positive axillary lymph nodes.
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39after mastectomy. However, long-term outcomes after radiation
therapy are not well described (3-5). Randomized clinical trials
have established that adjuvant chemotherapy or hormonal treat-
ment prolongs the survival of breast cancer patients. As a result
of these studies, large numbers of women with breast cancer
now receive one or both of these treatments postoperatively. A
number of randomized trials have also shown that overall survival
(OS) in patients with small tumors was the same whether they
were treated with limited surgery plus irradiation or total mastec-
tomy. For this reason, many patients are now treated locally with
conservative measures, such as lumpectomy plus axillary dis-
section and irradiation to residual breast tissue; some also receive
adjuvant systemic therapy. Total mastectomy, however is still the
treatment of choice for many patients. The role of radiotherapy
(RT) after mastectomy has been evaluated in several randomized
trials. Overall, these studies have shown a significant reduction in
LR with PMRT but no improvement in long-term survival, irre-
spective of nodal status. Radiotherapy has been evaluated main-
ly in trials in which chemotherapy was not given. The widespread
use of adjuvant chemotherapy calls for a reassessment of RT,
because the efficacy of systemic therapy in preventing local or
regional recurrence after mastectomy is only moderate and it is
not clear whether local or regional control is required for pro-
longed survival in patients who also receive adjuvant chemother-
apy (6-15). 
The trial by Ragaz et al. from British Columbia, Canada, reports a
5-year LR rate of 21% among women who did not undergo RT
and 10% among those who received radiation; 10-year rates were
25% and 13%, respectively. Similarly, the Danish trial by
Overgaard et al. reports a 114-month rate of LR alone of 26% for
women given chemotherapy without RT and 5% for those given
both chemotherapy and RT. Rates of LR are considerably lower
in the United States. Fisher et al. reported a 6.2% rate of LR
among women treated without RT at 8 years; Lichter et al. report-
ed 7.8% at 68 months; and Jacobson et al. reported 8.6% at 10.1
years. Notably, Fisher et al. find the same rate of LR in stage I and
II disease, which probably reflects a positive effect of adjuvant
chemotherapy. Parenthetically, the actuarial eight year rate of LR
at other European centers was 9% in pts treated with mastecto-
my, as reported by van Dongen et al. Thus, the incidence of LR
after mastectomy reported by Ragaz et al. and Overgaard et al. is
extremely high (16-24).
A more comprehensive meta-analysis concerning postmastecto-
my radiation was recently updated by the Early Breast Cancer
Trialists’ Collaborative Group. This group analyzed the actual data
from over 15 000 patients treated in clinical trials investigating the
use of PMRT. The data from this analysis showed that PMRT
reduced isolated LR rates (1).
Aim of our study was to assess to role of PMRT on LR rate and
OS in high risk premenopausal and postmenopausal breast can-
cer pts. We defined high-risk status for pts with tumors grater
than 3 cm diameter and positive axillary ln.
PATIENTS AND METHODS
From 1994 till 1999, 233 patients underwent modified radical
mastectomy for breast cancer at Clinical Centre of Montenegro.
Among them there was 92 premenopausal (median age was 44
years) and 141 postmenopausal women (median age was 60
years). Traditional prognostic factors were used to assess risk of
LR: 84 patients were node-negative, 71 had 1 to3 LN positive,
and 71 patients had 4 and more positive ln; 103 patients had
tumor less than 3 cm diameter and 130 had tumors grater than 3
cm (Table 1).
To be eligible for the study a woman had to have no evidence of
metastatic disease as determined by physical examination, bio-
chemical tests, chest radiography, bone radiography and no other
previous or concomitant malignant disease. 
According to this, PMRT was applied in 125 patients. RT was
delivered to the chest wall, including the surgical scar and region-
al LN (i.e., supraclavicular, infraclavicular and axillary nodes as
well as internal mammary nodes) depending on the primary site
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Table 1. Patients￿ characteristicsof the tumor. Each patient had received PMRT on the surgical
scar (125 patients), patients with positive axillary LN on the
supra- and infraclavicular ln, on the axilla after incomplete dis-
section, and patients with inner tumor localization - on the inter-
nal mammary nodes. The intended dose was a median absorbed
dose in the target volume of either 50 Gy, given in 25 fractions
over a period of 5 weeks, or 48 Gy given in 22 fractions over a
period of 4.5 weeks, according to report 50 of the ICRU
(International Commission on Radiation Units and
Measurements). The recommended field arrangement involved
the use of an anterior photon field against the supraclavicular,
infraclavicular, axillary regions, the internal mammary nodes and
tangential fields against the chest wall. The patients were treated
on the linear accelerator, 6 MeV energy, Clinac 600 C, Varian.
Also, 194 patients had systemic therapy (chemotherapy and/or
hormonal therapy). A combination of cyclophosphamide (600 mg
per square meter of body surface area), methotrexate (40 mg per
square meter of body surface area) and fluorouracil (600 mg per
square meter of body surface area) was given 1 and 8 day, IV
every four weeks, up to six cycles, with the first cycle beginning
three to four weeks after surgery. Patients who were assigned to
RT plus CMF started RT concomitantly with chemotherapy.
Among them there were pts with FAC chemotherapy (fluorouracil
500 mg per square meter of body surface area; Adriamycin 50
mg per square meter; cyclophosphamide 500 mg per square
meter, IV, 1 day, every 3 weeks, up to 6 cycles) preceding RT.
Hormonal therapy was given as tamoxifen for postmenopausal
women and ovarian ablation +/- tamoxifen for premenopausal
women according prognostic factors. Same dose and schedule
of chemotherapy was given in the group of patients without RT.  
The patients were followed with clinical examination at regular
intervals for up to 5 years and further tested only if they had
symptoms or evidence of recurrent disease. 
LR was defined as the appearance of the disease on the chest
wall and axillary ln. The lengths of time until treatment failure were
measured from the date of mastectomy. Disease free survival
(DFS) was defined as the duration of survival without LR or dis-
tant metastases, cancer in the opposite breast, or other malignant
disease. OS was calculated as the length of time until death, irre-
spective of cause. The values were compared by chi square test.
We used the life table method to estimate the probability of treat-
ment failure for the end points of DFS and OS (16). The median
potential follow-up was 49 months.
RESULTS 
By the time of the analysis (median follow-up, 49 months) the LR
was observed in 42 patients while 191 patients were free of. The
probability of DFS was significantly higher in the group that
received RT plus chemotherapy than in the group treated only
with chemotherapy. Among those with PMRT, 10 patients (12%)
had LR while 32 patients (33%) with no PMRT (p=0.0001). In the
group of patients with LR event 5-year OS was 28% while 70% in
the group of patients free of (p=0.00001) (Figure 1). There was
statistically significant advantage for PMRT in the group of
patients with 1 to 3 positive LN as well as for 4 and more positive
LN group (p=0.0008). In addition there was statistically signifi-
cant difference between PMRT group and no PMRT group for DFS
(74% vs. 50%, 5-year DFS, p=0.0001) and OS (71% v. 53%, 5-
year OS, p=0.0422) (Figure 2, 3).
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Figure 1. Locoregional recurrence/No locoregional recurrence - In the group of 42
patients with LR event 5-year OS was 28% while 70% in the group of patients free
of (191 patients) (p= 0.00001)
Figure 2. Postmastectomy radiotherapy/No postmastectomy radiotherapy - There
was statistically significant difference between PMRT group and no PMRT group
for DFS (74 % vs. 50 %, 5-year DFS, p=0.0001) (233 patients)
Figure 3. Postmastectomy radiotherapy/No postmastectomy radiotherapy - There
was statistically significant difference between PMRT group and no PMRT group
for OS (71 % vs. 53 %, 5-year OS, p=0.0422) (233 patients)DISCUSSION 
Trials of postoperative radiotherapy for breast cancer conducted
during the 1960s and 1970s showed significant reductions in
rates of LR but no improvement in OS. Failure of PMRT to
improve OS was explained with micrometastatic nature of breast
cancer even in an early stage of the disease. Additional concern
was raised by data suggesting that irradiated patients have
reduced survival rates due to either immunosuppression or car-
diac complications. In the late 1970s, adjuvant chemotherapy
became a standard treatment for high-risk premenopausal
patients with breast cancer. The use of adjuvant RT subsequent-
ly declined, because it did not appear to prolong survival.
Nevertheless, there are reasons to reconsider RT including the
limited value of adjuvant chemotherapy for bulky disease, a syn-
ergistic effect of chemotherapy plus radiation on residual locore-
gional tumor, and the possibility that eliminating bulky disease
with radiation may improve the effect of chemotherapy, because
chemotherapy may be more effective when the overall disease
burden is low (17,18). Also, in the recent years it has become
recognized that DFS and not only the OS represents very impor-
tant treatment objective being defined as time with good quality of
life (18).
Surgical technique is known to affect the incidence of local recur-
rence. The data thus seem more relevant to the role of RT after
total mastectomy rather than modified radical mastectomy. The
value of axillary irradiation in the former case is established; the
rate of recurrence in untreated, clinically negative axillae is about
20 percent as opposed to 1 to 2 percent after axillary node dis-
section or irradiation. The National Surgical Adjuvant Breast and
Bowel Project (in Protocol B-04) detected no difference in the OS
of patients who underwent primary or delayed axillary dissection
or RT.
Our results indicate that the addition of RT to adjuvant chemother-
apy after modified radical mastectomy reduces LR and improves
survival (PMRT group vs. no PMRT group for DFS [74% vs. 50%,
5-year DFS, p=0.0001) and OS [71% vs. 53%, 5-year OS,
p=0.0422]). 
Previous studies of RT showed improvement in the control of
locoregional tumors and suggested improvement in survival.
During the surgical procedure some of the cancer cells are
implanted within the scar region and could be spread by lym-
phatics to surrounding cutaneous tissue. The postoperative RT
reduces this long-term risk to 10-12% (2-5). 
There might have been important variations in the extent of the
surgery. Our surgeons found relatively few LN in the axilla, but the
number also relies on the pathologist who counted the LN in the
specimen. More than half of the recurrences were on the chest
wall. Recurrences on the chest wall and in the axilla (without con-
comitant distant metastases) were treated with curative intent.
Most patients who did not receive RT were treated with resection
of the recurrent tumor followed by RT, whereas pts who had
received RT were treated with surgery alone. 
The significant difference in OS between the group treated with RT
plus chemotherapy and the group given chemotherapy alone indi-
cates that second line treatment cannot compensate for inade-
quate primary therapy. 
Our study indicates that optimal results of the treatment of breast
cancer pts can be achieved only by controlling both locoregional
and systemic tumors. With current surgical methods of treatment,
RT as treatment modality should be applied in purpose to achieve
good locoregional control, especially in high-risk breast cancer
patients and also in combination with adjuvant chemotherapy to
achieve better OS.
CONCLUSION 
PMRT reduces LR rate and improves OS in premenopausal and
postmenopausal breast cancer patients with tumors grater than
3cm diameter and positive axillary ln.
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